科笛-B新药CU-20401 II期临床获显著疗效数据
科笛-B（02487）发布公告，宣布其潜在1类新药CU-20401（重组突变胶原酶）在中国开展的II期临床试验已获得顶线数据，且达到了主要研究终点，结果具有统计学显著性及临床意义。该临床试验为多中心、随机、双盲及安慰剂对照试验，共入组108例受试者，分析显示低剂量和高剂量CU-20401组的治疗有效率均高于安慰剂对照组，且有效率差异具有统计学意义。
在安全性方面，CU-20401组未发生严重不良事件，整体展现出显著且稳健的疗效优势，安全性良好。CU-20401的作用机制为选择性作用于附着在脂肪组织上的细胞外基质，预期能有效减少局部脂肪堆积。公司提醒股东及潜在投资者在买卖股份时需审慎行事，因无法确保最终成功开发及销售CU-20401。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10